Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd., explained in plain language.
-
New hope for lung cancer: experimental drug HB0025 faces off against standard therapy
Disease control Not yet recruitingThis study compares a new drug called HB0025 combined with chemotherapy against the standard treatment (tislelizumab plus chemotherapy) for people with advanced nonsquamous non-small cell lung cancer that cannot be removed by surgery. About 500 adults aged 18 to 75 will receive o…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New lung cancer combo aims to outperform standard immunotherapy
Disease control Not yet recruitingThis study tests whether a new drug called HB0025, combined with chemotherapy, works better than the standard immunotherapy pembrolizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer who have not had prior treatment. About 480 adults will be rand…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New antibody shot could zap stubborn acne
Symptom relief Not yet recruitingThis early-stage study tests a new drug called HB0043 in 21 adults with moderate to severe acne. The drug is a bispecific antibody that targets two inflammatory pathways (IL-17A and IL-36R) thought to drive acne. The main goal is to see if it safely reduces acne lesions and impro…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated May 17, 2026 08:49 UTC